Regional Anesthesia Antithrombotic Guidelines

ESAIC/ESRA 2022 vs ASRA PM 2025

DOACs (Direct Oral Anticoagulants)
Apixaban Rivaroxaban Edoxaban Dabigatran
LMWH (Low Molecular Weight Heparins)
Enoxaparin Dalteparin Tinzaparin Nadroparin
UFH & Indirect Xa Inhibitor
UFH (IV) UFH (SC) Fondaparinux
Vitamin K Antagonists
Warfarin
Antiplatelets
Aspirin Clopidogrel Prasugrel Ticagrelor Ticlopidine Cilostazol
GP IIb/IIIa Inhibitors
Abciximab Eptifibatide Tirofiban
Other Anticoagulants
Argatroban Bivalirudin

-

-

Recommended Hold Time

-
-
ESAIC / ESRA 2022
ASRA PM 2025
Disclaimer: This app provides guideline-based reference information and does not replace clinical judgment. Always verify with current guidelines and consider individual patient factors.
Sources: Kietaibl et al., Eur J Anaesthesiol 2022;39:100-132 (ESAIC/ESRA) · Kopp et al., Reg Anesth Pain Med 2025 (ASRA 5th ed). Data cross-checked against source PDFs: 2026-07-13.